Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Draft scope assessment: unclear. Attached because the study's own record describes refractory disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Cumulative incidence rate of treatment related mortality with relapse as a competing risk, assessed at 30 months.

Source null

→

secondary · POSTED

Kaplan-Meier estimates for overall survival (OS) and progression free survival (PFS) assessed at two years.

Source null

→

secondary · POSTED

Response Rates

Source null

→

secondary · POSTED

Median number of days after transplantation to a neutrophil count less than 500 neutrophils per microliter and a platelet count less than 50,000 platelets per microliter.

Source null

→

secondary · POSTED

Incidence and Severity of Acute Graft-versus-host Disease (GVHD) and Chronic GVHD.

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id: NCT00119392
trial label: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
applicability: unclear
applicability note: Attached because the study's own record describes refractory disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 5
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
outcome key
om-0000
source section id
NCT00119392-om-0000
source outcome index
0
endpoint
Treatment Related Mortality (TRM)
endpoint definition
Cumulative incidence rate of treatment related mortality with relapse as a competing risk, assessed at 30 months.
time origin
At day +100
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
outcome key
om-0001
source section id
NCT00119392-om-0001
source outcome index
1
endpoint
Overall and Progression-free Survival
endpoint definition
Kaplan-Meier estimates for overall survival (OS) and progression free survival (PFS) assessed at two years.
time origin
Up to 8 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
outcome key
om-0002
source section id
NCT00119392-om-0002
source outcome index
2
endpoint
Response Rates
endpoint definition
Response Rates
time origin
Up to 8 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
outcome key
om-0003
source section id
NCT00119392-om-0003
source outcome index
3
endpoint
Engraftment and Hematopoietic Toxicity
endpoint definition
Median number of days after transplantation to a neutrophil count less than 500 neutrophils per microliter and a platelet count less than 50,000 platelets per microliter.
time origin
At day +100
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
outcome key
om-0004
source section id
NCT00119392-om-0004
source outcome index
4
endpoint
Incidence and Severity of Acute Graft-versus-host Disease (GVHD) and Chronic GVHD.
endpoint definition
Incidence and Severity of Acute Graft-versus-host Disease (GVHD) and Chronic GVHD.
time origin
At day +84
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
outcome key
om-0000
arm key
OG000
arm label
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)
regimen
See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00119392-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
outcome key
om-0001
arm key
OG000
arm label
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)
regimen
See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00119392-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
outcome key
om-0002
arm key
OG000
arm label
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)
regimen
See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI
analyzed count
42
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00119392-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
outcome key
om-0003
arm key
OG000
arm label
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)
regimen
See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00119392-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
outcome key
om-0004
arm key
OG000
arm label
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)
regimen
See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00119392-om-0004#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-ruxience-816f4f4a
nct id
NCT00119392
harm key
EG000
source section id
NCT00119392-ae
event group key
EG000
event group label
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)
serious affected
8
serious at risk
40
other affected
36
other at risk
40
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice